Could anti-HCV treatment prevent recurrence of hepatocellular carcinoma in HIV-infected patients? Two case reports

Highly active antiretroviral therapy (HAART) has proven long-term efficacy in human immunodeficiency virus (HIV) infection. Combination therapy with pegylated interferon and ribavirin has become the standard of care in patients with both hepatitis C virus (HCV) chronic hepatitis and HIV/HCV co-infec...

Full description

Saved in:
Bibliographic Details
Published inInfection Vol. 41; no. 1; pp. 199 - 202
Main Authors Cenderello, G., Pontali, E., Cassola, G., Torresin, A.
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer-Verlag 01.02.2013
Springer Nature B.V
Subjects
Antiretroviral agents
Antiretroviral Therapy, Highly Active
Antiviral Agents - administration & dosage
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Brief Report
Carcinoma, Hepatocellular - prevention & control
Case reports
Chronic infection
Coinfection
Family Medicine
General Practice
Hepatitis
Hepatitis C
Hepatitis C virus
Hepatitis C, Chronic - drug therapy
Hepatocellular carcinoma
Highly active antiretroviral therapy
HIV
HIV Infections - drug therapy
Human immunodeficiency virus
Humans
Infectious Diseases
Interferon
Internal Medicine
Liver cancer
Liver Neoplasms - prevention & control
Male
Medicine
Medicine & Public Health
Middle Aged
Patients
Recurrence
Ribavirin
Therapy
Treatment Outcome
White Blood Cell Decrease
Start Combination Treatment
Human Immunodeficiency Virus
Sustained Virological Response
Nelfinavir
Online AccessGet full text

Cover

More Information
Summary:Highly active antiretroviral therapy (HAART) has proven long-term efficacy in human immunodeficiency virus (HIV) infection. Combination therapy with pegylated interferon and ribavirin has become the standard of care in patients with both hepatitis C virus (HCV) chronic hepatitis and HIV/HCV co-infection. Data on the safety and efficacy of combination therapy in chronic hepatitis C patients with hepatocellular carcinoma (HCC) is scarce and even more so in HIV/HCV co-infected subjects. We report the successful administration of both HAART and anti-HCV therapies in two HIV/HCV co-infected patients after HCC eradication. These encouraging results might argue for the feasibility of an aggressive approach in the management of co-infected patients with HCC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0300-8126
1439-0973
1439-0973
DOI:10.1007/s15010-012-0353-3